دورية أكاديمية
أعرض في EDS

Modern management of the axilla.

التفاصيل البيبلوغرافية
العنوان: Modern management of the axilla.
المؤلفون: Boland MR; Department of Breast Surgery, St Vincent's University Hospital, Dublin, Ireland.
المصدر: Journal of surgical oncology [J Surg Oncol] 2024 Jul; Vol. 130 (1), pp. 23-28. Date of Electronic Publication: 2024 Apr 21.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0222643 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9098 (Electronic) Linking ISSN: 00224790 NLM ISO Abbreviation: J Surg Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005-> : Hoboken, NJ : Wiley-Liss
Original Publication: New York, Plenum.
مواضيع طبية MeSH: Axilla* , Lymph Node Excision*/methods , Sentinel Lymph Node Biopsy* , Breast Neoplasms*/surgery , Breast Neoplasms*/pathology , Breast Neoplasms*/therapy, Humans ; Female ; Lymphatic Metastasis
مستخلص: Surgical management of the axilla has evolved considerably in recent years, with a strong focus on de-escalation to minimise morbidity whilst maintaining oncological outcomes. Current trials will focus on the omission of Sentinel node biopsy in select groups of patients, while axillary lymph node dissection will be reserved for those with more aggressive disease.
(© 2024 The Authors. Journal of Surgical Oncology published by Wiley Periodicals LLC.)
References: Fisher B, Montague E, Redmond C, et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer: a first report of results from a prospective randomized clinical trial. Cancer. 1977;39(6):2827‐2839.
Krag DN, Anderson SJ, Julian TB, et al. Sentinel‐lymph‐node resection compared with conventional axillary‐lymph‐node dissection in clinically node‐negative patients with breast cancer: overall survival findings from the NSABP B‐32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927‐933.
Veronesi U, Paganelli G, Galimberti V, et al. Sentinel‐node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph‐nodes. Lancet. 1997;349(9069):1864‐1867.
Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10‐year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918‐926.
Rutgers EJ, Donker M, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303‐1310. doi:10.1016/S1470‐2045(14)70460‐7.
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981‐22023 AMAROS): a randomised, multicentre, open‐label, phase 3 non‐inferiority trial. Lancet Oncol. 2014;15(12):1303‐1310.
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel‐node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297‐305.
de Boniface J, Frisell J, Andersson Y, et al. Survival and axillary recurrence following sentinel node‐positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017;17:379.
Sávolt Á, Péley G, Polgár C, et al. Eight‐year follow up result of the OTOASOR trial: the optimal treatment of the axilla – surgery or radiotherapy after positive sentinel lymph node biopsy in early‐stage breast cancer. Eur J Surg Oncol (EJSO). 2017;43(4):672‐679.
Tinterri C, Gentile D, Gatzemeier W, et al. Preservation of axillary lymph nodes compared with complete dissection in T1–2 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR‐ONE multicenter randomized clinical trial. Ann Surg Oncol. 2022;29(9):5732‐5744.
Roldan‐Vasquez E, Bharani T, Mitri S, et al. Expanding access to immediate lymphatic reconstruction through an axillary surgery referral program: a 6‐year single‐center experience. Ann Surg Oncol. 2023;31:2025‐2031. doi:10.1245/s10434-023-14573-2.
Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long‐term follow‐up of CALGB 9343. J Clin Oncol. 2013;31(19):2382‐2387.
Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast‐preserving surgery in women with localized cancer of the breast. N Engl J Med. 1993;328(22):1587‐1591.
Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971‐977.
International Breast Cancer Study G, Rudenstam CM, Zahrieh D, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10‐93. J Clin Oncol: Off J Am Soc Clin Oncol. 2006;24(3):337‐344.
Gentilini OD, Botteri E, Sangalli C, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA oncology. 2023;9(11):1557‐1564.
Gentilini O, Botteri E, Dadda P, et al. Physical function of the upper limb after breast cancer surgery. Results from the SOUND (Sentinel node vs. Observation after axillary Ultra‐souND) trial. Eur J Surg Oncol (EJSO). 2016;42(5):685‐689.
Reimer T, Stachs A, Nekljudova V, et al. Restricted axillary staging in clinically and sonographically node‐negative early invasive breast cancer (c/iT1–2) in the context of breast conserving therapy: first results following commencement of the Intergroup‐Sentinel‐Mamma (INSEMA) trial. Geburtshilfe Frauenheilkd. 2017;77(02):149‐157.
Van Roozendaal LM, Vane MLG, Van Dalen T, et al. Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow‐up: a Dutch randomized controlled multicentre trial (BOOG 2013‐08). BMC Cancer. 2017;17(1):459.
Jung JG, Ahn SH, Lee S, et al. No axillary surgical treatment for lymph node‐negative patients after ultra‐sonography [NAUTILUS]: protocol of a prospective randomized clinical trial. BMC Cancer. 2022;22(1):189.
Li J, Cheng J, Liu G, et al. Feasibility of sentinel lymph node biopsy omission after integration of 18F‐FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial. Cancer Biol Med. 2022;19(7):1100.
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2019;30(8):1194‐1220.
Evans A, Trimboli RM, Athanasiou A, et al. Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Imaging. 2018;9(4):449‐461. doi:10.1007/s13244-018-0636-z.
Boughey JC. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node‐positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455‐1461.
Al‐Hilli Z, Hoskin TL, Day CN, Habermann EB, Boughey JC. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol. 2018;25(2):482‐493. doi:10.1245/s10434-017-6263-y.
Boland MR, McVeigh TP, O'Flaherty N, et al. Impact of receptor phenotype on nodal burden in patients with breast cancer who have undergone neoadjuvant chemotherapy. BJS Open. 2017;1(2):39‐45. doi:10.1002/bjs5.6.
Boland MR, Prichard RS, Daskalova I, et al. Axillary nodal burden in primary breast cancer patients with positive pre‐operative ultrasound guided fine needle aspiration cytology: management in the era of ACOSOG Z011. Eur J Surg Oncol (EJSO). 2015;41(4):559‐565.
Pilewskie M, Mautner SK, Stempel M, Eaton A, Morrow M. Does a positive axillary lymph node needle biopsy result predict the need for an axillary lymph node dissection in clinically node‐negative breast cancer patients in the ACOSOG Z0011 era? Ann Surg Oncol. 2016;23:1123‐1128.
Harris CK, Tran HT, Lee K, et al. Positive ultrasound‐guided lymph node needle biopsy in breast cancer may not mandate axillary lymph node dissection. Ann Surg Oncol. 2017;24:3004‐3010.
Lim GH, Upadhyaya VS, Acosta HA, Lim JMA, Allen Jr. JC, Leong LCH. Preoperative predictors of high and low axillary nodal burden in Z0011 eligible breast cancer patients with a positive lymph node needle biopsy result. Eur J Surg Oncol. 2018;44(7):945‐950.
Man V, Luk WP, Fung LH, Kwong A. The role of pre‐operative axillary ultrasound in assessment of axillary tumor burden in breast cancer patients: a systematic review and meta‐analysis. Breast Cancer Res Treat. 2022;196(2):245‐254. doi:10.1007/s10549-022-06699-w.
Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2022;20(6):691‐722. doi:10.6004/jnccn.2022.0030.
Henke G, Knauer M, Ribi K, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node‐positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase‐III trial. Trials. 2018;19(1):667.
Crown A, Sevilimedu V, Morrow M. Palpable adenopathy does not indicate high‐volume axillary nodal disease in hormone receptor‐positive breast cancer. Ann Surg Oncol. 2021;28(11):6060‐6068. doi:10.1245/s10434-021-09943-7.
Yoo T‐K, Kang BJ, Kim SH, et al. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy‐proven axillary lymph node metastasis. Breast Cancer Res Treat. 2020;181:403‐409.
Cocco D, Shah C, Wei W, Wilkerson A, Grobmyer SR, Al‐Hilli Z. Axillary lymph node dissection can be omitted in patients with limited clinically node‐positive breast cancer: a National Cancer Database analysis. Br J Surg. 2022;109(12):1293‐1299.
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel‐lymph‐node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609‐618.
Boileau J‐F, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy‐proven node‐positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258‐264.
Tee SR, Devane LA, Evoy D, et al. Meta‐analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy‐proven node‐positive breast cancer. Br J Surg. 2018;105(12):1541‐1552.
Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node‐positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072‐1078.
Boughey JC, Ballman KV, Le‐Petross HT, et al. Identification and resection of clipped node decreases the false‐negative rate of sentinel lymph node surgery in patients presenting with node‐positive breast cancer (T0‐T4, N1‐N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802‐807.
Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261(2):378‐382.
van Nijnatten T, Simons JM, Smidt ML, et al. A novel less‐invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node‐positive breast cancer by combining radioactive iodine seed localization in the axilla with the sentinel node procedure (RISAS): a Dutch prospective multicenter validation study. Clin Breast Cancer. 2017;17(5):399‐402.
Gasparri ML, de Boniface J, Poortmans P, et al. Axillary surgery after neoadjuvant therapy in initially node‐positive breast cancer: international EUBREAST survey. Br J Surg. 2022;109(9):857‐863. doi:10.1093/bjs/znac217.
Simons JM, van Nijnatten TJA, van der Pol CC, Luiten EJT, Koppert LB, Smidt ML. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node‐positive breast cancer: a systematic review and meta‐analysis. Ann Surg. 2019;269(3):432‐442.
Montagna G, Lee MK, Sevilimedu V, Barrio AV, Morrow M. Is nodal clipping beneficial for node‐positive breast cancer patients receiving neoadjuvant chemotherapy? Ann Surg Oncol. 2022;29(10):6133‐6139.
Hartmann S, Reimer T, Gerber B, Stubert J, Stengel B, Stachs A. Wire localization of clip‐marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy. Eur J Surg Oncol. 2018;44(9):1307‐1311. doi:10.1016/j.ejso.2018.05.035.
Keelan S, Boland MR, Ryan ÉJ, et al. Long‐term survival in patients with node‐positive breast cancer who undergo sentinel lymph node biopsy alone after neoadjuvant chemotherapy: meta‐analysis. Br J Surg. 2023;110(3):324‐332. doi:10.1093/bjs/znac413.
Marie-Jeanne TFD, Peeters V. Avoiding sentinel lymph node biopsy in select clinical node negative breast cancer patients after neoadjuvant systemic therapy: the ASICS trial. 2020. Available from https://clinicaltrials.gov/study/NCT04225858?cond=asics%20breast&rank=1#publications.
Reimer T, Glass A, Botteri E, Loibl S, D. Gentilini O. Avoiding axillary sentinel lymph node biopsy after neoadjuvant systemic therapy in breast cancer: rationale for the prospective, multicentric EUBREAST‐01 trial. Cancers. 2020;12(12):3698.
Samiei S, Simons JM, Engelen SME, Beets‐Tan RGH, Classe J‐M, Smidt ML. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node‐positive disease: a systematic review and meta‐analysis. JAMA surgery. 2021;156(6):e210891‐e.
Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC. Association of low nodal positivity rate among patients with ERBB2‐positive or triple‐negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA surgery. 2018;153(12):1120‐1126.
Van der Noordaa MEM, Van Duijnhoven FH, Cuijpers FNE, et al. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node‐negative breast cancer. Br J Surg. 2021;108(6):667‐674.
Kuerer HM, Smith BD, Krishnamurthy S, et al. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single‐arm, phase 2 trial. Lancet Oncol. 2022;23(12):1517‐1524.
Oncology AfCTi. Comparison of axillary lymph node dissection with axillary radiation for patients with node‐positive breast cancer treated with chemotherapy. National Library of Medicine (US): ClinicalTrials gov [Internet] Bethesda (MD). Cited July 13, 2015. http://clinicaltrials.gov/show.2015.
Sanders SB, Hoskin TL, Stafford AP, Boughey JC. Factors influencing non‐sentinel lymph node involvement in patients with positive sentinel lymph node (s) after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2022;29(12):7769‐7778.
فهرسة مساهمة: Keywords: axilla; breast; cancer; surgery
تواريخ الأحداث: Date Created: 20240421 Date Completed: 20240714 Latest Revision: 20240714
رمز التحديث: 20240714
DOI: 10.1002/jso.27649
PMID: 38643485
قاعدة البيانات: MEDLINE
الوصف
تدمد:1096-9098
DOI:10.1002/jso.27649